Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 4, Number 1—March 1998
Synopsis

Proteases of Malaria Parasites: New Targets for Chemotherapy

Philip J. RosenthalComments to Author 
Author affiliation: San Francisco General Hospital and University of California, San Francisco, California, USA

Main Article

Table 3

Protease targets for chemotherapy

Effective inhibitorsa
Protease Biologic role Compound (Reference) In vitrob
(IC50; μM) In vivoc (mg/kg/day)
Pf68 Erythrocyte invasion GlcA-Val-Leu-Gly-Lys-NHC2H5 (40) 900
Plasmepsin I Hemoglobin degradation SC-50083 (41)
Ro 40-4388 (42) 2-5
0.25
Plasmepsin II Hemoglobin degradation Compound 7 (43) 20
Falcipain Hemoglobin degradation Z-Phe-Arg-CH2F (44) 0.064
Mu-Phe-HPh-CH2F (45) ~0.03 400
Mu-Leu-HPh-VSPh (46) 0.01
Oxalic bis ((2-hydroxy-1-naph- thylmethylene)hydrazide) (47) 7
1-(2,5-dichlorophenyl)-3- (4-quinolinyl)-2-propen-1-one (48) 0.23
7-chloro-1,2-dihydro-2-(2,3-di- methoxy-phenyl)-5,5-dioxide- 4-(1H,10H)-phenothiazinone (49) 2

aThe structures of these compounds and details of the described studies are in the references noted.
bAssays compared the development of new ring-form parasites or the uptake of [3H]hypoxanthine by treated and control parasites.
cCure of Plasmodium vinckei-infected mice.

Main Article

References
  1. Walsh  JA. Disease problems in the Third World. Ann N Y Acad Sci. 1989;569:1–16. DOIPubMedGoogle Scholar
  2. Oaks  SC, Mitchell  VS, Pearson  GW, Carpenter  CCJ, eds. Malaria: obstacles and opportunities. Washington: National Academy Press; 1991.
  3. Olliaro  P, Cattani  J, Wirth  D. Malaria, the submerged disease. JAMA. 1996;275:230–3. DOIPubMedGoogle Scholar
  4. Hoffman  SL, Miller  LH. Perspectives on malaria vaccine development. In: Hoffman SL, editor. Malaria vaccine development. Washington: ASM Press; 1996. p. 1-13.
  5. Alonso  PL, Lindsay  SW, Armstrong  JRM, Conteh  M, Hill  AG, David  PH, The effect of insecticide-treated bed nets on mortality of Gambian children. Lancet. 1991;337:1499–502. DOIPubMedGoogle Scholar
  6. Collins  FH, Besansky  NJ. Vector biology and the control of malaria in Africa. Science. 1994;264:1874–5. DOIPubMedGoogle Scholar
  7. Centers for Disease Control. Recommendations for the prevention of malaria among travelers. JAMA. 1990;263:2729–40. DOIPubMedGoogle Scholar
  8. Murphy  GS, Basri  H, Purnomo , Andersen  EM, Bangs  MJ, Mount  DL, . Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1993;341:96–100. DOIPubMedGoogle Scholar
  9. Panisko  DM, Keystone  JS. Treatment of malaria—1990. Drugs. 1990;39:160–89. DOIPubMedGoogle Scholar
  10. Keystone  JS. Prevention of malaria. Drugs. 1990;39:337–54. DOIPubMedGoogle Scholar
  11. Wyler  DJ. Malaria chemoprophylaxis for the traveler. N Engl J Med. 1993;329:31–7. DOIPubMedGoogle Scholar
  12. White  JJ. The treatment of malaria. N Engl J Med. 1996;335:800–6. DOIPubMedGoogle Scholar
  13. Olliaro  P, Nevill  C, LeBras  J, Ringwald  P, Mussano  P, Garner  P, Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet. 1996;348:1196–201. DOIPubMedGoogle Scholar
  14. Palmer  KJ, Holliday  SM, Brogden  RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993;45:430–75. DOIPubMedGoogle Scholar
  15. Luzzi  GA, Peto  TEA. Adverse effects of antimalarials: an update. Drug Saf. 1993;8:295–311. DOIPubMedGoogle Scholar
  16. Hellgren  U, Kihamia  CM, Bergqvist  Y, Lebbad  M, Premji  Z, Rombo  L. Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. Trans R Soc Trop Med Hyg. 1990;84:469–73. DOIPubMedGoogle Scholar
  17. Bradley  DJ, Warhurst  DC. Malaria prophylaxis: guidelines for travellers from Britain. BMJ. 1995;310:709–14.PubMedGoogle Scholar
  18. Bryson  HM, Goa  KL. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992;43:236–58. DOIPubMedGoogle Scholar
  19. Meshnick  SR, Taylor  TE, Kamchonwongpaisan  S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev. 1996;60:301–15.PubMedGoogle Scholar
  20. de Vries  PJ, Dien  TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs. 1996;52:818–36. DOIPubMedGoogle Scholar
  21. Haile  LG, Flaherty  JF. Atovaquone: a review. Ann Pharmacother. 1993;27:1488–94.PubMedGoogle Scholar
  22. Radloff  PD, Philipps  J, Nkeyi  M, Hutchinson  D, Kremsner  PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996;347:1511–4. DOIPubMedGoogle Scholar
  23. Ringwald  P, Bickii  J, Basco  L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet. 1996;347:24–8. DOIPubMedGoogle Scholar
  24. Gordeuk  VR, Thuma  PE, Brittenham  GM, Biemba  G, Zulu  S, Simwanza  G, Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg. 1993;48:193–7.PubMedGoogle Scholar
  25. Gordeuk  V, Thuma  P, Brittenham  G, McLaren  C, Parry  D, Backenstose  A, Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med. 1992;327:1473–7.PubMedGoogle Scholar
  26. Anderson  SL, Berman  J, Kuschner  R, Wesche  D, Magill  A, Wellde  B, Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med. 1995;123:771–3.PubMedGoogle Scholar
  27. McKerrow  JH, Sun  E, Rosenthal  PJ, Bouvier  J. The proteases and pathogenicity of parasitic protozoa. Annu Rev Microbiol. 1993;47:821–53. DOIPubMedGoogle Scholar
  28. Blackman  MJ, Holder  AA. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol. 1992;50:307–16. DOIPubMedGoogle Scholar
  29. Perkins  ME. Erythrocyte invasion by the malarial merozoite: recent advances. Exp Parasitol. 1989;69:94–9. DOIPubMedGoogle Scholar
  30. Bernard  F, Schrevel  J. Purification of a Plasmodium berghei neutral endopeptidase and its localization in merozoite. Mol Biochem Parasitol. 1987;26:167–74. DOIPubMedGoogle Scholar
  31. Rosenthal  PJ, Kim  K, McKerrow  JH, Leech  JH. Identification of three stage-specific proteinases of Plasmodium falciparum. J Exp Med. 1987;166:816–21. DOIPubMedGoogle Scholar
  32. Braun-Breton  C, Rosenberry  TL, Pereira da Silva  L. Induction of the proteolytic activity of a membrane protein in Plasmodium falciparum by phosphatidyl inositol-specific phospholipase C. Nature. 1988;332:457–9. DOIPubMedGoogle Scholar
  33. Roggwiller  E, Bétoulle  MEM, Blisnick  T, Braun Breton  C. A role for erythrocyte band 3 degradation by the parasite gp76 serine protease in the formation of the parasitophorous vacuole during invasion of erythrocytes by Plasmodium falciparum. Mol Biochem Parasitol. 1996;82:13–24. DOIPubMedGoogle Scholar
  34. Deguercy  A, Hommel  M, Schrevel  J. Purification and characterization of 37-kilodalton proteases from Plasmodium falciparum and Plasmodium berghei which cleave erythrocyte cytoskeletal components. Mol Biochem Parasitol. 1990;38:233–44. DOIPubMedGoogle Scholar
  35. Knapp  B, Hundt  E, Nau  U, Küpper  HA. Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch. Mol Biochem Parasitol. 1989;32:73–84. DOIPubMedGoogle Scholar
  36. Li  W-B, Bzik  DJ, Horii  T, Inselburg  J. Structure and expression of the Plasmodium falciparum SERA gene. Mol Biochem Parasitol. 1989;33:13–26. DOIPubMedGoogle Scholar
  37. Knapp  B, Nau  U, Hundt  E, Küpper  HA. A new blood stage antigen of Plasmodium falciparum highly homologous to the serine-stretch protein SERP. Mol Biochem Parasitol. 1991;44:1–14. DOIPubMedGoogle Scholar
  38. Roggwiller  E, Fricaud  A-C, Blisnick  T, Braun-Breton  C. Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes. Mol Biochem Parasitol. 1997;86:49–59. DOIPubMedGoogle Scholar
  39. Schrevel  J, Grellier  P, Mayer  R, Monsigny  M. Neutral proteases involved in the reinvasion of erythrocytes by Plasmodium merozoites. Biol Cell. 1988;64:233–44. DOIPubMedGoogle Scholar
  40. Mayer  R, Picard  I, Lawton  P, Grellier  P, Barrault  C, Monsigny  M, Peptide derivatives specific for a Plasmodium falciparum proteinase inhibit the human erythrocyte invasion by merozoites. J Med Chem. 1991;34:3029–35. DOIPubMedGoogle Scholar
  41. Francis  SE, Gluzman  IY, Oksman  A, Knickerbocker  A, Mueller  R, Bryant  ML, Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 1994;13:306–17.PubMedGoogle Scholar
  42. Moon  RP, Tyas  L, Certa  U, Rupp  K, Bur  D, Jacquet  C, Expression and characterisation of plasmepsin I from Plasmodium falciparum. Eur J Biochem. 1997;244:552–60. DOIPubMedGoogle Scholar
  43. Silva  AM, Lee  AY, Gulnik  SV, Majer  P, Collins  J, Bhat  TN, Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc Natl Acad Sci U S A. 1996;93:10034–9. DOIPubMedGoogle Scholar
  44. Rosenthal  PJ, Wollish  WS, Palmer  JT, Rasnick  D. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J Clin Invest. 1991;88:1467–72. DOIPubMedGoogle Scholar
  45. Rosenthal  PJ, Lee  GK, Smith  RE. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J Clin Invest. 1993;91:1052–6. DOIPubMedGoogle Scholar
  46. Rosenthal  PJ, Olson  JE, Lee  GK, Palmer  JT, Klaus  JL, Rasnick  D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob Agents Chemother. 1996;40:1600–3.PubMedGoogle Scholar
  47. Ring  CS, Sun  E, McKerrow  JH, Lee  GK, Rosenthal  PJ, Kuntz  ID, Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci U S A. 1993;90:3583–7. DOIPubMedGoogle Scholar
  48. Li  R, Kenyon  GL, Cohen  FE, Chen  X, Gong  B, Dominguez  JN, In vitro antimalarial activity of chalcones and their derivatives. J Med Chem. 1995;38:5031–7. DOIPubMedGoogle Scholar
  49. Domínguez  JN, López  S, Charris  J, Iarruso  L, Lobo  G, Semenov  A, Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. J Med Chem. 1997;40:2726–32. DOIPubMedGoogle Scholar
  50. Rosenthal  PJ, Meshnick  SR. Hemoglobin catabolism and iron utilization by malaria parasites. Mol Biochem Parasitol. 1996;83:131–9. DOIPubMedGoogle Scholar
  51. Slater  AFG. Malaria pigment. Exp Parasitol. 1992;74:362–5. DOIPubMedGoogle Scholar
  52. Bond  JS, Butler  PE. Intracellular proteases. Annu Rev Biochem. 1987;56:333–64. DOIPubMedGoogle Scholar
  53. Gluzman  IY, Francis  SE, Oksman  A, Smith  CE, Duffin  KL, Goldberg  DE. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J Clin Invest. 1994;93:1602–8. DOIPubMedGoogle Scholar
  54. Gyang  FN, Poole  B, Trager  W. Peptidases from Plasmodium falciparum cultured in vitro. Mol Biochem Parasitol. 1982;5:263–73. DOIPubMedGoogle Scholar
  55. Aissi  E, Charet  P, Bouquelet  S, Biguet  J. Endoprotease in Plasmodium yoelii nigeriensis. Comp Biochem Physiol. 1983;74B:559–66.
  56. Sherman  IW, Tanigoshi  L. Purification of Plasmodium lophurae cathepsin D and its effects on erythrocyte membrane proteins. Mol Biochem Parasitol. 1983;8:207–26. DOIPubMedGoogle Scholar
  57. Sato  K, Fukabori  Y, Suzuki  M. Plasmodium berghei: a study of globinolytic enzyme in erythrocytic parasite. Zbl Bakt Hyg A. 1987;264:487–95.
  58. Bailly  E, Savel  J, Mahouy  G, Jaureguiberry  G. Plasmodium falciparum: isolation and characterization of a 55-kDa protease with a cathepsin D-like activity from P. falciparum. Exp Parasitol. 1991;72:278–84. DOIPubMedGoogle Scholar
  59. Goldberg  DE, Slater  AFG, Beavis  R, Chait  B, Cerami  A, Henderson  GB. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J Exp Med. 1991;173:961–9. DOIPubMedGoogle Scholar
  60. Vander Jagt  DL, Hunsaker  LA, Campos  NM, Scaletti  JV. Localization and characterization of hemoglobin-degrading aspartic proteinases from the malarial parasite Plasmodium falciparum. Biochim Biophys Acta. 1992;1122:256–64.PubMedGoogle Scholar
  61. Dame  JB, Reddy  GR, Yowell  CA, Dunn  BM, Kay  J, Berry  C. Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol. 1994;64:177–90. DOIPubMedGoogle Scholar
  62. Hill  J, Tyas  L, Phylip  LH, Kay  J, Dunn  BM, Berry  C. High level expression and characterisation of plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett. 1994;352:155–8. DOIPubMedGoogle Scholar
  63. Dluzewski  AR, Rangachari  K, Wilson  RJM, Gratzer  WB. Plasmodium falciparum: protease inhibitors and inhibition of erythrocyte invasion. Exp Parasitol. 1986;62:416–22. DOIPubMedGoogle Scholar
  64. Rosenthal  PJ, McKerrow  JH, Aikawa  M, Nagasawa  H, Leech  JH. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J Clin Invest. 1988;82:1560–6. DOIPubMedGoogle Scholar
  65. Vander Jagt  DL, Caughey  WS, Campos  NM, Hunsaker  LA, Zanner  MA. Parasite proteases and antimalarial activities of protease inhibitors. Prog Clin Biol Res. 1989;313:105–18.PubMedGoogle Scholar
  66. Rosenthal  PJ. Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp Parasitol. 1995;80:272–81. DOIPubMedGoogle Scholar
  67. Bailly  E, Jambou  R, Savel  J, Jaureguiberry  G. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and pepstatin A (aspartyl protease inhibitor). J Protozool. 1992;39:593–9.PubMedGoogle Scholar
  68. Gamboa de Domínguez  ND, Rosenthal  PJ. Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. Blood. 1996;87:4448–54.PubMedGoogle Scholar
  69. Asawamahasakda  W, Ittarat  I, Chang  C-C, McElroy  P, Meshnick  SR. Effects of antimalarials and protease inhibitors on plasmodial hemozoin production. Mol Biochem Parasitol. 1994;67:183–91. DOIPubMedGoogle Scholar
  70. Rosenthal  PJ, McKerrow  JH, Rasnick  D, Leech  JH. Plasmodium falciparum: inhibitors of lysosomal cysteine proteinases inhibit a trophozoite proteinase and block parasite development. Mol Biochem Parasitol. 1989;35:177–84. DOIPubMedGoogle Scholar
  71. Salas  F, Fichmann  J, Lee  GK, Scott  MD, Rosenthal  PJ. Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect Immun. 1995;63:2120–5.PubMedGoogle Scholar
  72. Francis  SE, Gluzman  IY, Oksman  A, Banerjee  D, Goldberg  DE. Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation. Mol Biochem Parasitol. 1996;83:189–200. DOIPubMedGoogle Scholar
  73. Rosenthal  PJ, Nelson  RG. Isolation and characterization of a cysteine proteinase gene of Plasmodium falciparum. Mol Biochem Parasitol. 1992;51:143–52. DOIPubMedGoogle Scholar
  74. Kamchonwongpaisan  S, Samoff  E, Meshnick  SR. Identification of hemoglobin degradation products in Plasmodium falciparum. Mol Biochem Parasitol. 1997;86:179–86. DOIPubMedGoogle Scholar
  75. Vander Jagt  DL, Baack  BR, Hunsaker  LA. Purification and characterization of an aminopeptidase from Plasmodium falciparum. Mol Biochem Parasitol. 1984;10:45–54. DOIPubMedGoogle Scholar
  76. Curley  GP, O'Donovan  SM, McNally  J, Mullally  M, O'Hara  H, Troy  A, Aminopeptidases from Plasmodium falciparum, Plasmodium chabaudi, and Plasmodium berghei. J Eukaryot Microbiol. 1994;41:119–23. DOIPubMedGoogle Scholar
  77. Kolakovich  KA, Gluzman  IY, Duffin  KL, Goldberg  DE. Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production. Mol Biochem Parasitol. 1997;87:123–35. DOIPubMedGoogle Scholar
  78. Rockett  KA, Playfair  JHL, Ashall  F, Targett  GAT, Angliker  H, Shaw  E. Inhibition of intraerythrocytic development of Plasmodium falciparum by proteinase inhibitors. FEBS Lett. 1990;259:257–9. DOIPubMedGoogle Scholar

Main Article

Page created: December 13, 2010
Page updated: December 13, 2010
Page reviewed: December 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external